Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Post-Transcriptional Regulation is a Therapeutic Vulnerability of Acute Myeloid Leukemia

Award Number: F30CA310107
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 04/17/2026
PERIOD OF PERFORMANCE END DATE: 04/16/2030

Group Awards By:

View Award Description

Post-Transcriptional Regulation is a Therapeutic Vulnerability of Acute Myeloid Leukemia - PROJECT SUMMARY/ABSTRACT Acute myeloid leukemia (AML) has persistently maintained a low ~32% 5-year survival rate in spite of over three decades of medical research. With approximately 22,010 in the U.S being diagnosed with AML and 11,090 dying from the disease yearly, there remains an urgent need to develop new therapies and treatment strategies. Understanding the key protein drivers of AML and the regulatory mechanisms governing expression of these proteins has provided us with an opportunity to specifically target the disease. The most common variants of AML in both pediatric and adult patients depend upon the chromatin binding MLL protein complex. Recently developed small molecule menin-inhibitors have demonstrated remarkable clinical success by inhibiting MLL complex formation. However, close to 40% of patients treated with menin inhibitors for prolonged periods develop resistance and subsequently relapse, demonstrating an urgent need for combination therapy. Our lab has previously shown that a critical component of the MLL complex, LEDGF, is sensitive to perturbations in translation due to its short half-life. I demonstrated that LEDGF protein expression can be inhibited with the RNA helicase eIF4A1 inhibitor silvestrol, and that silvestrol has potent anti -AML properties. The following aims will test the hypothesis that eIF4A1 inhibition is an effective AML therapy in vivo, capable of circumventing menin inhibitor resistance. In Aim 1 I will generate novel mouse models of menin inhibitor resistant adult and pediatric AML to test the efficacy of eIF4A1 inhibition as an AML therapy. In Aim 2 I will identify the molecular mechanisms by which eIF4A1 contributes to LEDGF translation, exploring the role of eIF4A1 in maintaining AML cells. The long-term objectives of this project are to characterize a clinically relevant new approach to treat AML and uncover molecular mechanisms governing mRNA translation. This fellowship application is sponsored by Dr. Daisuke Nakada, PhD, an expert in hematopoietic stem cell biology and acute myeloid leukemia biology. This training plan is designed to 1) provide mentorship from experts in science and medicine; 2) develop general and field-specific scientific knowledge in stem cell, chromatin, and RNA biology; 3) grow my scientific communication skills and form professional networks; and 4) develop clinical skills and knowledge toward a pediatrician-scientist career. The clinical and scientific training environment is at Baylor College of Medicine, located in the heart of the Texas Medical Center with close ties to institutions such as Texas Children's Hospital and MD Anderson Cancer Center. This environment is ideal to foster scientific and clinical growth toward my long-term goal of becoming a physician scientist in the field of pediatric hematology-oncology.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $54,107 )
2026	2026	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Research Manpower	000	1	4/17/2026	NEW	$54,107
2026	2026	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Cancer Research Manpower	001	1	4/17/2026	NEW	$0
														Subtotal = $54,107

Grand Total All Awards = $54,107

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Post-Transcriptional Regulation is a Therapeutic Vulnerability of Acute Myeloid Leukemia

Award Number: F30CA310107

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 04/17/2026

PERIOD OF PERFORMANCE END DATE: 04/16/2030

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer